This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical Faculty Heidelberg (S-904/2019). Written informed consent was obtained from the patients’ parents for the laboratory analysis of patient material. Fibroblasts and HEK 293T and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FCS, 100 U/mL of penicillin, and 100 µg/mL of streptomycin (see
Supplementary Materials for details, including
Table S3 regarding the used cell lines). For protein extract preparation, 80–90% confluent cell monolayers of a T75 flask were washed with ice-cold PBS, harvested, and stored at −80 °C.
For metabolic labeling, the HEK 293T cells were cultured in
DMEM for SILAC (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% (
v/
v) FBS, 100 U/mL of penicillin, 100 µg/mL of streptomycin, 1% (
v/
v) GlutaMAX
® (Thermo Fisher Scientific), 0.55 mM of [
13C
6,
15N
4]-arginine, and 0.82 mM of [
13C
6,
15N
2]-lysine (Cambridge Isotopes, Tewksbury, MA, USA) for at least seven passages [34 ]. The cells were harvested and stored as described above. The preparation of the membrane protein fraction was performed as described (see
Supplementary Materials for details) [24 (
link)].
Sakson R., Beedgen L., Bernhard P., Alp K.M., Lübbehusen N., Röth R., Niesler B., Luzarowski M., Shevchuk O., Mayer M.P., Thiel C, & Ruppert T. (2024). Targeted Proteomics Reveals Quantitative Differences in Low-Abundance Glycosyltransferases of Patients with Congenital Disorders of Glycosylation. International Journal of Molecular Sciences, 25(2), 1191.